Francois M Vallette
Overview
Explore the profile of Francois M Vallette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2877
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliver L, Landais Y, Gratas C, Cartron P, Paris F, Heymann D, et al.
Stem Cell Res Ther
. 2024 Nov;
15(1):424.
PMID: 39538257
Background: The interaction between mesenchymal stem cells (MSC) and Glioblastoma (GBM), although potentially of the highest importance, is ill-understood. This is due, in part, to the lack of relevant experimental...
2.
Loussouarn D, Oliver L, Salaud C, Samarut E, Bourgade R, Beroud C, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370866
Only a minority of patients with glioblastoma (GBM) respond to immunotherapy, and always only partially. There is a lack of knowledge on immune distribution in GBM and in its tumor...
3.
Bikfalvi A, Alves da Costa C, Avril T, Barnier J, Bauchet L, Brisson L, et al.
Trends Cancer
. 2023 Mar;
9(8):692.
PMID: 36997420
No abstract available.
4.
Oliver L, Alvarez-Arenas A, Salaud C, Jimenez-Sanchez J, Calvo G, Belmonte-Beitia J, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831643
We have developed a 3D biosphere model using patient-derived cells (PDCs) from glioblastoma (GBM), the major form of primary brain tumors in adult, plus cancer-activated fibroblasts (CAFs), obtained by culturing...
5.
Vales S, Bacola G, Biraud M, Touvron M, Bessard A, Geraldo F, et al.
EBioMedicine
. 2023 Jan;
88:104448.
PMID: 36689913
No abstract available.
6.
Bikfalvi A, Alves da Costa C, Avril T, Barnier J, Bauchet L, Brisson L, et al.
Trends Cancer
. 2022 Nov;
9(1):9-27.
PMID: 36400694
Glioblastoma (GBM) is the most deadly type of malignant brain tumor, despite extensive molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has been recognized as an...
7.
Jubelin C, Munoz-Garcia J, Griscom L, Cochonneau D, Ollivier E, Heymann M, et al.
Cell Biosci
. 2022 Sep;
12(1):155.
PMID: 36089610
Cancer is a multifactorial disease that is responsible for 10 million deaths per year. The intra- and inter-heterogeneity of malignant tumors make it difficult to develop single targeted approaches. Similarly,...
8.
Rabe M, Fonteneau L, Oliver L, Morales-Molina A, Jubelin C, Garcia-Castro J, et al.
Front Cell Dev Biol
. 2022 Jun;
10:835273.
PMID: 35693929
We have observed a drug-tolerant/persister state in a human glioblastoma (GBM) cell line after exposure to temozolomide, the standard-of-care chemotherapeutic agent for GBM. We used a multicolor lentiviral genetic barcode...
9.
Oliver L, Lalier L, Salaud C, Heymann D, Cartron P, Vallette F
Cancer Drug Resist
. 2022 May;
3(3):287-301.
PMID: 35582442
Glioblastoma (GBM) represents the main form of brain tumors in adults, and one of the most aggressive cancers overall. The treatment of GBM is a combination of surgery (when possible),...
10.
Garnier D, Ratcliffe E, Briand J, Cartron P, Oliver L, Vallette F
Biomedicines
. 2022 Jan;
10(1).
PMID: 35052791
Glioblastoma (GBM) is the most aggressive brain tumor, and despite initial response to chemo- and radio-therapy, the persistence of glioblastoma stem cells (GSCs) unfortunately always results in tumor recurrence. It...